CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
ROCKVILLE, Md. and BEIJING, Sept. 20, 2021 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Alexander Zukiwski, Chief Medical Officer of CASI Pharmaceuticals, will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Details for the virtual conference is as follows.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 21st
Time: 12:05 PM (EDT)
Webcast or external link of the company presentation will be available under “Events & Presentations” in the “Investors Relations” section of CASI’s website. Archived replays will be available for approximately 90 days following the event.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.
|
COMPANY CONTACT: CASI Pharmaceuticals, Inc. Rui Zhang 240-864-2643 ir@casipharmaceuticals.com |
INVESTOR CONTACT: Solebury Trout Xuan Yang 646-378-2975 xyang@troutgroup.com |
